AstraZeneca AZNannounced that it has secured an FDA approval for the label expansion of its marketed drug, Tagrisso (osimertinib), for first-line treatment of adult patients with locally-advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR mutations.
FDA Nods to AstraZeneca's Tagrisso for First-Line NSCLC
Понравилась статья? Подпишитесь на канал, чтобы быть в курсе самых интересных материалов
Подписаться